Lipoprotein (a) levels and clinical decision-making: data from a Mexican cohort at a tertiary medical institution
Authors:
- Ivette Cruz-BautistaICIvette Cruz-Bautista
- Yuscely Flores-JuradoYFYuscely Flores-Jurado
- Guillermo Roa-ÁlvarezGRGuillermo Roa-Álvarez
- Daniel Benjamin Elías-LopezDEDaniel Benjamin Elías-Lopez
- Ricardo Federico Hernández-FrancoRHRicardo Federico Hernández-Franco
- Arsenio Vargas-VázquezAVArsenio Vargas-Vázquez
- Raymundo Valdez-EcheverríaRVRaymundo Valdez-Echeverría
- Liliana Muñoz-HernándezLMLiliana Muñoz-Hernández
- Roopa MehtaRMRoopa Mehta
Open Access
- 26 May 2025
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-12
Abstract
Approximately 20% of the global population has a Lp(a) concentrations above 50 mg/dL (> 125nmol/L), yet many remain unaware of the associated cardiovascular risks. In Mexico, routine measurement of Lp(a) is uncommon. This study aimed to investigate the frequency of Lp(a) testing, and the clinical actions taken by physicians upon detecting elevated Lp(a) concentrations in patients at a tertiary medical institution. Using an algorithm-based screening system, we reviewed the clinical and biochemical data of patients with Lp(a) measurements from 2019 to 2024. Data were retrieved from the laboratory information system and electronic health records. Complementary assessment data were obtained from the radiology and cardiology departments. Of the 150,083 individuals evaluated at the institution, only 830 (0.5%) underwent Lp(a) testing, with testing rates increasing from 0.037% in 2019 to 0.24% in 2023. Elevated Lp(a) concentrations (> 50 mg/dL) were found in 21% of patients, and 2.2% had concentrations > 180 mg/dL. Patients with elevated Lp(a) had significantly higher rates of atherosclerotic cardiovascular disease (ASCVD) (p < 0.001) and familial hypercholesterolemia (p < 0.004) than those with lower Lp(a) levels. Interestingly, diabetes prevalence was higher in those with Lp(a) < 4 mg/dL (51.5% vs. 33.4%, p < 0.001). Despite the cardiovascular risk, only 26% of patients with elevated Lp(a) levels received interventions to modify risk factors. Lp(a) testing was infrequent in a tertiary medical setting. Clinical interventions to modify cardiovascular risk factors were insufficient among patients with elevated Lp(a). These findings highlight the need for greater awareness among healthcare providers and the development of comprehensive screening and management algorithms to mitigate Lp(a) -related cardiovascular risk.Keywords
This publication has 49 references indexed in Scilit:
- Lp(a): When and how to measure itAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2020
- Coronary Artery Calcium is Associated with LPA Gene variant rs7765803-C in Mexican Mestizo Population. The GEA ProjectRevista de Investigación Clínica, 2020
- Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and DiabetesJACC, 2019
- HEART UK consensus statement on Lipoprotein(a): A call to actionAtherosclerosis, 2019
- 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular riskAtherosclerosis, 2019
- Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapyJournal of Clinical Lipidology, 2019
- Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid AssociationJournal of Clinical Lipidology, 2019
- CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic SubjectsArteriosclerosis, Thrombosis, and Vascular Biology, 2017
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD FibrosisAmerican Journal of Gastroenterology, 2017
- NAFLD fibrosis score: A prognostic predictor for mortality and liver complications among NAFLD patientsWorld Journal of Gastroenterology, 2013